BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34155918)

  • 1. Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?
    Negri F; Gnetti L; Pedrazzi G; Silini EM; Porta C
    Future Oncol; 2021 Sep; 17(27):3579-3584. PubMed ID: 34155918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
    Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
    J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
    Yau T; Yao TJ; Chan P; Wong H; Pang R; Fan ST; Poon RT
    Oncologist; 2011; 16(9):1270-9. PubMed ID: 21885876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
    Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
    Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.
    Houessinon A; Gicquel A; Bochereau F; Louandre C; Nyga R; Godin C; Degonville J; Fournier E; Saidak Z; Drullion C; Barbare JC; Chauffert B; François C; Pluquet O; Galmiche A
    Cancer Lett; 2016 Jan; 370(2):242-9. PubMed ID: 26546044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
    Tsuchiya K; Asahina Y; Matsuda S; Muraoka M; Nakata T; Suzuki Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Nishimura T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
    Cancer; 2014 Jan; 120(2):229-37. PubMed ID: 24122122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
    Kegasawa T; Sakamori R; Maesaka K; Yamada R; Tahata Y; Urabe A; Kodama T; Hikita H; Imanaka K; Ohkawa K; Hiramatsu N; Oshita M; Yamada Y; Inada M; Yakushijin T; Imai Y; Tatsumi T; Takehara T
    Dig Dis Sci; 2021 May; 66(5):1720-1729. PubMed ID: 32556820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.
    Memon K; Kulik L; Lewandowski RJ; Wang E; Ryu RK; Riaz A; Nikolaidis P; Miller FH; Yaghmai V; Baker T; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
    J Hepatol; 2012 May; 56(5):1112-1120. PubMed ID: 22245905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
    Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
    J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
    Kuo YH; Wu IP; Wang JH; Hung CH; Rau KM; Chen CH; Kee KM; Hu TH; Lu SN
    Invest New Drugs; 2018 Apr; 36(2):307-314. PubMed ID: 28466374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
    Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Shinohara M; Kikuchi Y; Igarashi Y; Sumino Y
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):863-7. PubMed ID: 27431630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
    Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
    J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
    Llovet JM; Peña CE; Lathia CD; Shan M; Meinhardt G; Bruix J;
    Clin Cancer Res; 2012 Apr; 18(8):2290-300. PubMed ID: 22374331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Kuzuya T; Asahina Y; Tsuchiya K; Tanaka K; Suzuki Y; Hoshioka T; Tamaki S; Kato T; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Izumi N
    Oncology; 2011; 81(3-4):251-8. PubMed ID: 22116493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
    Labeur TA; Berhane S; Edeline J; Blanc JF; Bettinger D; Meyer T; Van Vugt JLA; Ten Cate DWG; De Man RA; Eskens FALM; Cucchetti A; Bonnett LJ; Van Delden OM; Klümpen HJ; Takkenberg RB; Johnson PJ
    Liver Int; 2020 Jan; 40(1):215-228. PubMed ID: 31579990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.